论文部分内容阅读
2010年1月12日,某预防接种门诊在接种无细胞百日咳-白喉-破伤风联合疫苗(Diphtheria,Tetanus and Acellular Pertussis Combined Vaccine,DTaP)后,发现一例持久性硬结。现将调查结果报告如下。1调查资料患儿,男,本地户籍,2008年5月27日出生,足月剖腹产,出生体重3600克。2008年9月1日接种第一剂由北京天坛生物制品有限公司生产的、批号为2008030202的DTaP0.5毫升(ml),10月15日接种同批号第二剂DTaP0.5ml,均无接种反应。11月13日,在左上臂三角肌内接种第三剂同一厂家生产、批号为2008050102的DTaP后,局部出现红肿,经热敷等对症处理,一周后红肿消
On January 12, 2010, one of the vaccination clinics found one case of persistent sclerosis after vaccination with the Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine (DTaP). The survey results are reported below. A survey of children, male and local domicile, born May 27, 2008, full-term caesarean section, birth weight 3600 grams. On September 1, 2008, the first dose of DTaP 0.5 ml (lot number 2008030202) produced by Beijing Tiantan Biological Products Co., Ltd. was inoculated on the 1st of October 2008 and 0.5 ml of DTaP 0.5 ml . November 13, in the left upper quadrant deltoid inoculation third dose of the same manufacturer, lot number 2008050102 of DTaP, the local redness, the heat treatment and other symptomatic treatment, a week after the swelling